Secondary interstitial lung disease in childhood and adulthood associated with a systemic vasculitis

Secondary interstitial lung disease (ILD) associated with systemic vasculitis refers to a group of conditions in which inflammation of blood vessels (vasculitis) leads to damage and scarring of the lung tissue (interstitium). This condition can manifest in both childhood and adulthood and occurs as a secondary complication of systemic vasculitides such as granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome), and other forms of systemic vasculitis. The lungs are a primary target organ, but because the underlying disease is systemic, multiple organ systems may be affected, including the kidneys, skin, joints, peripheral nerves, and upper respiratory tract. Key pulmonary symptoms include progressive shortness of breath (dyspnea), chronic cough, and reduced exercise tolerance. Diffuse alveolar hemorrhage may occur, presenting with hemoptysis (coughing up blood). Imaging typically reveals ground-glass opacities, reticular patterns, or honeycombing on high-resolution CT scan. Pulmonary function tests often show a restrictive pattern with reduced diffusing capacity. Systemic symptoms such as fever, fatigue, weight loss, and signs of involvement of other organs (e.g., glomerulonephritis, skin purpura, neuropathy) are commonly present. Treatment is directed at the underlying systemic vasculitis and typically involves immunosuppressive therapy. First-line treatment often includes high-dose corticosteroids combined with cyclophosphamide or rituximab for severe disease. Maintenance therapy may involve azathioprine, methotrexate, or mycophenolate mofetil. Management of the interstitial lung disease component may also require supportive measures such as supplemental oxygen and pulmonary rehabilitation. Early diagnosis and aggressive treatment of the vasculitis are critical to preventing irreversible lung fibrosis and preserving pulmonary function. Prognosis depends on the specific type of vasculitis, the extent of lung involvement, and the response to immunosuppressive treatment.

Common questions about Secondary interstitial lung disease in childhood and adulthood associated with a systemic vasculitis